| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.04B | -57.4% |
| Gross profit | ¥0.00B | — |
| Operating income | ¥0.00B | — |
| Net income | ¥0.00B | +439.3% |
| Gross margin | 12.9% | Net margin 9.5% |
| Revenue Q/Q | -14.8% | — |
The filing did not disclose a revenue breakdown for this period.
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.03B | 87.1% |
| R&D | ¥0.00B | 2.9% |
| SG&A | ¥0.00B | 11.1% |
| Tax & other | ¥-0.00B | -2.2% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
新迅达 ・ 新光药业 ・ 科大国创 ・ 爱司凯 ・ 世名科技 ・ 辰安科技 ・ 博思软件 ・ ST应急 ・ 幸福蓝海 ・ 健帆生物 ・ 领湃科技 ・ 优博讯
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies